These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29937862)

  • 1. Does the use of recombinant TSH in preparation for I-131 scintigraphy scan affect hearing function?
    Doğan M; Durmuş K; Hasbek Z; Altuntaş EE
    J Otol; 2018 Mar; 13(1):20-24. PubMed ID: 29937862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
    Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
    J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
    Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
    Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using ¹³¹I-whole body scans to identify metastases of differentiated thyroid cancer.
    Liepe K
    Int J Surg; 2015 Apr; 16(Pt A):107-112. PubMed ID: 25771100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH.
    Bacher R; Hohberg M; Dietlein M; Wild M; Kobe C; Drzezga A; Schmidt M
    J Nucl Med; 2019 May; 60(5):631-637. PubMed ID: 30315143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
    Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
    Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Endocr Pract; 2013; 19(1):139-48. PubMed ID: 23186979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma.
    Dietlein M; Busemeyer S; Kobe C; Schmidt M; Theissen P; Schicha H
    Nuklearmedizin; 2010; 49(6):216-24. PubMed ID: 20877918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
    Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
    J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
    Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
    Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
    Freudenberg LS; Jentzen W; Petrich T; Frömke C; Marlowe RJ; Heusner T; Brandau W; Knapp WH; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2267-76. PubMed ID: 20661558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Inoue M; Nakamura K; Mizowaki T
    Ann Nucl Med; 2020 Oct; 34(10):736-741. PubMed ID: 32643022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.
    Ciappuccini R; Hardouin J; Heutte N; Vaur D; Quak E; Rame JP; Blanchard D; de Raucourt D; Bardet S
    Eur J Endocrinol; 2014 Aug; 171(2):247-52. PubMed ID: 24866576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence.
    Higuchi CRS; Fernanda P; Jurnior PA; Andrade FA; Corbo R; Vaisman M; Vaisman F; Bulzico D
    Front Nucl Med; 2021; 1():785768. PubMed ID: 39355636
    [No Abstract]   [Full Text] [Related]  

  • 18. Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis.
    Giovanella L; Garo ML; Campenní A; Petranović Ovčariček P; Görges R
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
    Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
    Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.